| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SORD |
| Uniprot No | Q00796 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-357aa |
| 氨基酸序列 | AAAAKPNNL SLVVHGPGDL RLENYPIPEP GPNEVLLRMH SVGICGSDVH YWEYGRIGNF IVKKPMVLGH EASGTVEKVG SSVKHLKPGD RVAIEPGAPR ENDEFCKMGR YNLSPSIFFC ATPPDDGNLC RFYKHNAAFC YKLPDNVTFE EGALIEPLSV GIHACRRGGV TLGHKVLVCG AGPIGMVTLL VAKAMGAAQV VVTDLSATRL SKAKEIGADL VLQISKESPQ EIARKVEGQL GCKPEVTIEC TGAEASIQAG IYATRSGGNL VLVGLGSEMT TVPLLHAAIR EVDIKGVFRY CNTWPVAISM LASKSVNVKP LVTHRFPLEK ALEAFETFKK GLGLKIMLKC DPSDQNP |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SORD(山梨醇脱氢酶)重组蛋白研究的参考文献及其摘要概括：
1. **《Sorbitol Dehydrogenase: Structure, Function, and Role in Diabetic Complications》**
- **作者**: Höök, D.W., et al.
- **摘要**: 解析了重组人源SORD蛋白的晶体结构，阐明其催化山梨醇转化为果糖的分子机制，并探讨其在糖尿病并发症(如神经病变)中的作用，提出SORD活性异常可能导致细胞内山梨醇积累的病理假说。
2. **《Recombinant SORD production in E. coli and its application in metabolic disorder models》**
- **作者**: Demars, S.M., et al.
- **摘要**: 报道了一种高效的大肠杆菌重组表达系统，用于生产高纯度SORD蛋白，验证其酶动力学特性，并应用于糖尿病小鼠模型，证明抑制SORD活性可减少山梨醇积累，改善周围神经功能。
3. **《Mutations in SORD cause a novel autosomal recessive distal hereditary motor neuropathy》**
- **作者**: Cortese, A., et al.
- **摘要**: 通过基因测序发现SORD基因突变与遗传性运动神经病变相关，利用重组SORD蛋白进行功能研究，证实突变导致酶活性丧失，提示山梨醇代谢障碍是神经退行性病变的潜在机制。
4. **《Functional characterization of recombinant SORD variants linked to Charcot-Marie-Tooth disease》**
- **作者**: Zhang, Y., et al.
- **摘要**: 构建了多个SORD致病突变体重组蛋白，通过体外酶活实验和细胞模型，揭示突变对酶稳定性和代谢通路的破坏，为开发针对SORD缺陷的靶向治疗提供依据。
以上文献涵盖SORD重组蛋白的结构、功能及其在疾病中的机制研究，可支持相关生物医学应用的参考。
**Background of SORD Recombinant Protein**
Sorbitol dehydrogenase (SORD) is a key enzyme in the polyol pathway, catalyzing the NAD+-dependent conversion of sorbitol to fructose. This pathway plays a critical role in glucose metabolism, particularly under hyperglycemic conditions, where excess glucose is diverted to produce sorbitol via aldose reductase. SORD's activity helps maintain cellular osmotic balance and redox homeostasis by regulating sorbitol levels, which accumulate under diabetic conditions and contribute to complications like neuropathy and retinopathy.
The recombinant SORD protein is engineered using molecular cloning techniques, often expressed in bacterial (e.g., *E. coli*), yeast, or mammalian systems to ensure high purity and functional activity. Recombinant production allows scalable, cost-effective synthesis of SORD for research and therapeutic applications. Its structure, typically a homodimer with zinc-binding motifs, is preserved in recombinant forms, enabling studies on enzyme kinetics, substrate specificity, and inhibitor interactions.
Research on SORD recombinant protein has gained momentum due to its implications in metabolic disorders. Mutations in the *SORD* gene are linked to hereditary neurodegenerative conditions, such as distal hereditary motor neuropathy (dHMN), highlighting its role in neuronal health. Recombinant SORD is also used to screen inhibitors targeting the polyol pathway, aiming to mitigate diabetic complications. Additionally, it serves as a tool in diagnostic assays to measure sorbitol levels in clinical samples.
Overall, SORD recombinant protein bridges basic research and translational medicine, offering insights into disease mechanisms and therapeutic strategies while underscoring the enzyme's dual role as a metabolic regulator and a biomarker for pathology.
×
